CPA
CLVS

Clear Perspective Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Clear Perspective Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,000
Closed -$203 – 149
2020
Q3 		$203 Buy
+10,000
New +$59.8K 0.1% 133

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clear Perspective Advisors's CLVS Position: Q4 2020 in Review

Clear Perspective Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2020, closing a stake of 10,000 shares — an estimated $203 sold.

Clear Perspective Advisors first reported a position in CLVS in Q3 2020 and held it in 1 quarter. The position peaked at $203 in Q3 2020. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.

  • Clear Perspective Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2020 after selling out during the quarter.
  • Clear Perspective Advisors sold 10,000 Clovis Oncology, Inc. shares in Q4 2020, an estimated $203.
  • Clear Perspective Advisors first reported a position in Clovis Oncology, Inc. in Q3 2020 and held it in 1 quarter.
  • Clear Perspective Advisors's Clovis Oncology, Inc. position peaked at $203 in Q3 2020.
  • 159 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2020.

Based on Clear Perspective Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.